Neuroprotective therapies: Preclinical reproducibility is only part of the problem.
Among the many unknowns in the translational path to developing drugs for acute stroke, addressing the reproducibility of preclinical data is only one piece of a multifaceted and incomplete puzzle (Llovera et al., this issue).